The "Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2026," or INSULIN Act of 2026, seeks to significantly reduce the financial burden of insulin for patients. Starting January 1, 2028, it mandates that group health plans and individual health insurance coverage eliminate deductibles for selected insulin products. Furthermore, it caps patient cost-sharing for these products at the lesser of $35 or 25% of the negotiated price per 30-day supply, net of all price concessions. The bill defines "selected insulin products" to ensure coverage for at least one of each dosage form and type of insulin available. It prohibits plans from imposing prior authorization or medical management requirements on these selected insulin products, except for clinically justified safety or quantity limits. Conforming amendments ensure that catastrophic health plans also cover selected insulin products before the deductible is met. To assist uninsured individuals, the legislation directs the Secretary of Health and Human Services to award a grant for establishing an Insulin Resource Center and Hotline . This center will provide fair and impartial information on manufacturer and other assistance programs, facilitate enrollment, and offer a 24/7 hotline staffed by navigators or health professionals. It will also conduct public education activities to raise awareness of available support. Additionally, the bill aims to foster competition in the insulin market by expediting the development and review of certain biosimilar biological products . The Secretary may designate a biosimilar as "competitive" if there is inadequate biosimilar competition, defined as fewer than three licensed biosimilars for a reference product and at least three years having passed since all exclusivity periods expired. The Government Accountability Office (GAO) is also tasked with conducting a study on the characteristics of uninsured individuals who use insulin, including demographic and economic factors, to inform future policy.